Inhibrx Biosciences (INBX) Enterprise Value (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Enterprise Value data on file, last reported at -$124.2 million in Q4 2025.

• On a quarterly basis, Enterprise Value rose 18.61% year-over-year to -$124.2 million in Q4 2025; TTM through Dec 2025 was -$124.2 million, a 18.61% increase from a year earlier, with the FY2025 full-year figure at -$124.2 million, up 18.61% from the prior year.
• Enterprise Value for Q4 2025 stood at -$124.2 million, up from -$153.1 million in the prior quarter.
• Over the last five years, Enterprise Value for INBX reached as high as -$124.2 million in Q4 2025 and fell as low as -$277.9 million in Q4 2023.
• Historically, Enterprise Value has averaged -$191.8 million across 3 years, with a median of -$191.4 million in 2024.
• Across the five-year window, Enterprise Value jumped 45.09% in 2024 and climbed 17.76% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$277.9 million in 2023, then soared by 45.09% to -$152.6 million in 2024, then grew by 18.61% to -$124.2 million in 2025.
• Per Business Quant data, the three most recent Enterprise Value figures were -$124.2 million in Q4 2025, -$153.1 million in Q3 2025, and -$186.6 million in Q2 2025.